I felt it was gonna be hard to send them down to him so i gave
There is one biosimilar competitor; a second is expected in several months. So as new drugs ramp, Remicade will likely shrink rapidly; and that’s just one aging drug.This problem explains why JNJ felt forced to pay a high P/E to acquire Actelion rather than produce growth via more internal drug development.JNJ has grown revenues at […]